Olema Pharmaceuticals (OLMA) Change in Acquisitions & Divestments (2021 - 2026)

Olema Pharmaceuticals (OLMA) has reported Change in Acquisitions & Divestments for 6 consecutive years, with $74.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments fell 23.83% year-over-year to $74.5 million; the TTM figure through Mar 2026 stood at $321.7 million (down 6.29% YoY), while the FY2025 annual figure was $345.0 million, up 14.38% from the prior year.
• Change in Acquisitions & Divestments eased to $74.5 million in Q1 2026 per OLMA's latest filing, from $91.2 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $148.8 million in Q1 2022 and bottomed at $38.8 million in Q3 2022.
• Historically, Change in Acquisitions & Divestments has averaged $75.1 million across 5 years, with a median of $70.5 million in 2023.
• On a YoY basis, Change in Acquisitions & Divestments climbed as much as 14775.0% in 2022 and fell as far as 67.56% in 2022.
• Olema Pharmaceuticals' Change in Acquisitions & Divestments stood at $61.0 million in 2022, then fell by 11.48% to $54.0 million in 2023, then surged by 38.53% to $74.8 million in 2024, then advanced by 21.87% to $91.2 million in 2025, then dropped by 18.32% to $74.5 million in 2026.
• Business Quant data shows OLMA's Change in Acquisitions & Divestments at $74.5 million in Q1 2026, $91.2 million in Q4 2025, and $88.9 million in Q3 2025.